Treace Medical Concepts financials
$4.62+3.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.4M | $47.2M | $62.5M | $50.2M | $47.4M | $52.6M | $68.7M | $45.1M | $44.5M | $51.1M | $62.2M | $40.8M |
| Gross profit | $35.6M | $37.4M | $50.4M | $39.7M | $37.8M | $41.9M | $55.5M | $36.1M | $35.7M | $41.0M | $50.7M | $32.8M |
| Gross margin | 78.5% | 79.3% | 80.6% | 79.1% | 79.7% | 79.7% | 80.7% | 80.1% | 80.2% | 80.2% | 81.6% | 80.4% |
| Operating income | -$14.8M | -$17.2M | -$5.9M | -$15.7M | -$16.9M | -$15.6M | -$204.0K | -$15.1M | -$21.4M | -$19.0M | -$7.0M | -$17.8M |
| Net income | -$15.9M | -$18.0M | -$9.4M | -$16.3M | -$17.4M | -$15.9M | -$501.0K | -$15.4M | -$21.2M | -$18.8M | -$6.3M | -$17.5M |
| Net margin | −35.0% | −38.1% | −15.0% | −32.4% | −36.7% | −30.3% | −0.7% | −34.1% | −47.7% | −36.7% | −10.1% | −43.0% |
| Diluted EPS | $-0.24 | $-0.28 | $-0.15 | $-0.26 | $-0.28 | $-0.25 | $-0.01 | $-0.25 | $-0.34 | $-0.30 | $-0.10 | $-0.28 |
| EBITDA | -$12.9M | -$16.3M | -$3.1M | -$12.9M | -$14.3M | -$13.1M | $2.0M | -$13.0M | -$19.3M | -$17.1M | -$7.0M | -$16.2M |
| Operating cash flow | -$4.7M | $7.2M | -$8.0M | -$9.1M | -$3.0M | $4.2M | -$4.2M | -$11.8M | -$13.9M | -$7.2M | $532.0K | -$9.5M |
| Free cash flow | -$6.9M | $4.2M | -$10.4M | -$11.9M | -$7.8M | $655.0K | -$7.3M | -$14.7M | -$15.6M | -$11.1M | -$1.7M | -$13.0M |
| Diluted shares | 65.0M | 64.6M | 63.9M | 63.5M | 63.0M | 62.7M | 62.3M | 62.2M | 62.1M | 61.8M | 61.7M | 61.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.6M | $9.5M | $10.7M | $7.7M | $8.1M | $13.4M |
| Short-term investments | $33.0M | $42.3M | $37.7M | $49.7M | $61.2M | $62.7M |
| Total debt | $56.0M | $55.8M | $55.6M | $53.5M | $53.5M | $53.4M |
| Total assets | $181.1M | $184.1M | $190.6M | $196.6M | $206.4M | $205.8M |
| Total liabilities | $113.3M | $106.9M | $103.2M | $107.4M | $108.8M | $100.5M |
| Shareholders' equity | $67.7M | $77.2M | $87.3M | $89.2M | $97.6M | $105.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology